[Treatment for hepatic osteodystrophy].
Chronic liver diseases, including liver cirrhosis, are caused by various pathogenesis, such as viral hepatitis, primary biliary cirrhosis, autoimmune hepatitis and steatohepatitis. There have not been enough clinical evidence about the treatment of hepatic osteodystrophy at the present time. Several reports suggested that bisphosphonates, such as alendronate, are effective for an increase in bone mineral density in patients with chronic liver disease. Vitamin D treatment might be useful for the frequent prevalence of vitamin D deficiency in the pathogenesis of hepatic oseodystrophy. The use of estrogens will be limited for the risk of liver dysfunction and hepatocellular carcinoma.
Department of Physiology and Regenerative Medicine,Kinki University Faculty of Medicine, Japan.
Hiroshi
H
Kaji
D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology; D004164:Diphosphonates / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism; D006801:Humans; D008107:Liver Diseases / Q000150:complications*; D014807:Vitamin D / Q000627:therapeutic use
D004164:Diphosphonates; D004965:Estrogen Antagonists; D004967:Estrogens; D014807:Vitamin D